Rebecca Y Kim1, Kathleen K Christians1, Mohammed Aldakkak1, Callisia N Clarke1, Ben George2, Mandana Kamgar2, Abdul H Khan3, Naveen Kulkarni4, William A Hall5, Beth A Erickson5, Douglas B Evans1, Susan Tsai6. 1. Department of Surgery, Mary Anne and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 2. Department of Medicine, Division of Hematology and Oncology, Mary Anne and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 3. Department of Medicine, Division of Gastroenterology and Hepatology, Mary Anne and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 4. Department of Radiology, Mary Anne and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 5. Department of Radiation Oncology, Mary Anne and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 6. Department of Surgery, Mary Anne and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. stsai@mcw.edu.
Abstract
BACKGROUND: Overall survival (OS) for operable pancreatic cancer (PC) is optimized when 4-6 months of nonsurgical therapy is combined with pancreatectomy. Because surgery renders the delivery of postoperative therapy uncertain, total neoadjuvant therapy (TNT) is gaining popularity. METHODS: We performed a retrospective cohort study of patients with operable PC and compared TNT with shorter course neoadjuvant therapy (SNT). Primary outcomes of interest included completion of neoadjuvant therapy (NT) and resection of the primary tumor, receipt of 5 months of nonsurgical therapy, and median OS. RESULTS: We reviewed 541 consecutive patients from 2009 to 2019 including 226 (42%) with resectable PC and 315 (58%) with borderline resectable (BLR) PC. The median age was 66 years (IQR [59, 72]), and 260 (48%) patients were female. TNT was administered to 89 (16%) patients and SNT was administered to 452 (84%). Both groups were equally likely to complete intended NT and surgery (p = 0.90). Patients who received TNT and surgical resection were more likely to have a complete pathologic response (8% vs 4%, p < 0.01) and were more likely to receive at least 5 months of nonsurgical therapy (67% vs 45%, p < 0.01). The median OS was 26 months [IQR (15, 57)]; not reached among patients treated with TNT, and 25 months [IQR (15, 56)] among patients treated with SNT (p = 0.19). CONCLUSIONS: TNT ensures the delivery of intended systemic therapy prior to a complicated operation without decreasing the chance of successful surgery; a window of operability was not lost. Patients who can tolerate SNT will likely benefit from TNT.
BACKGROUND: Overall survival (OS) for operable pancreatic cancer (PC) is optimized when 4-6 months of nonsurgical therapy is combined with pancreatectomy. Because surgery renders the delivery of postoperative therapy uncertain, total neoadjuvant therapy (TNT) is gaining popularity. METHODS: We performed a retrospective cohort study of patients with operable PC and compared TNT with shorter course neoadjuvant therapy (SNT). Primary outcomes of interest included completion of neoadjuvant therapy (NT) and resection of the primary tumor, receipt of 5 months of nonsurgical therapy, and median OS. RESULTS: We reviewed 541 consecutive patients from 2009 to 2019 including 226 (42%) with resectable PC and 315 (58%) with borderline resectable (BLR) PC. The median age was 66 years (IQR [59, 72]), and 260 (48%) patients were female. TNT was administered to 89 (16%) patients and SNT was administered to 452 (84%). Both groups were equally likely to complete intended NT and surgery (p = 0.90). Patients who received TNT and surgical resection were more likely to have a complete pathologic response (8% vs 4%, p < 0.01) and were more likely to receive at least 5 months of nonsurgical therapy (67% vs 45%, p < 0.01). The median OS was 26 months [IQR (15, 57)]; not reached among patients treated with TNT, and 25 months [IQR (15, 56)] among patients treated with SNT (p = 0.19). CONCLUSIONS: TNT ensures the delivery of intended systemic therapy prior to a complicated operation without decreasing the chance of successful surgery; a window of operability was not lost. Patients who can tolerate SNT will likely benefit from TNT.
Authors: Kathleen K Christians; Susan Tsai; Anna Mahmoud; Paul Ritch; James P Thomas; Lauren Wiebe; Tracy Kelly; Beth Erickson; Huamin Wang; Douglas B Evans; Ben George Journal: Oncologist Date: 2014-02-25
Authors: Janet E Murphy; Jennifer Y Wo; David P Ryan; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Jason E Faris; Andrew X Zhu; Lipika Goyal; Keith D Lillemoe; Thomas F DeLaney; Carlos Fernández-Del Castillo; Cristina R Ferrone; Theodore S Hong Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777
Authors: Alice C Wei; Fang-Shu Ou; Qian Shi; Xiomara Carrero; Eileen M O'Reilly; Jeffrey Meyerhardt; Robert A Wolff; Hedy L Kindler; Douglas B Evans; Vikram Deshpande; Joseph Misdraji; Eric Tamm; Dushyant Sahani; Malcolm Moore; Elliot Newman; Nipun Merchant; Jordan Berlin; Laura W Goff; Peter Pisters; Mitchell C Posner Journal: Ann Surg Oncol Date: 2019-08-15 Impact factor: 5.344
Authors: Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss Journal: Ann Surg Oncol Date: 2014-04-26 Impact factor: 5.344
Authors: Amudhan Pugalenthi; Mladjan Protic; Mithat Gonen; T Peter Kingham; Michael I D' Angelica; Ronald P Dematteo; Yuman Fong; William R Jarnagin; Peter J Allen Journal: J Surg Oncol Date: 2015-12-18 Impact factor: 3.454
Authors: Janet E Murphy; Jennifer Y Wo; David P Ryan; Jeffrey W Clark; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Leilana Ly; Christian V Baglini; Lawrence S Blaszkowsky; Cristina R Ferrone; Aparna R Parikh; Colin D Weekes; Ryan D Nipp; Eunice L Kwak; Jill N Allen; Ryan B Corcoran; David T Ting; Jason E Faris; Andrew X Zhu; Lipika Goyal; David L Berger; Motaz Qadan; Keith D Lillemoe; Nilesh Talele; Rakesh K Jain; Thomas F DeLaney; Dan G Duda; Yves Boucher; Carlos Fernández-Del Castillo; Theodore S Hong Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Andrew D Rhim; Emily T Mirek; Nicole M Aiello; Anirban Maitra; Jennifer M Bailey; Florencia McAllister; Maximilian Reichert; Gregory L Beatty; Anil K Rustgi; Robert H Vonderheide; Steven D Leach; Ben Z Stanger Journal: Cell Date: 2012-01-20 Impact factor: 41.582
Authors: Georgios Gemenetzis; Siobhan McKay; Samir Pathak; John Moir; Richard Laing; Nigel B Jamieson; Alastair L Young; Nikolaos A Chatzizacharias; Francesco Giovinazzo; Keith J Roberts Journal: Front Oncol Date: 2021-12-23 Impact factor: 6.244
Authors: Ottavia De Simoni; Marco Scarpa; Caterina Soldà; Francesca Bergamo; Sara Lonardi; Alberto Fantin; Pierluigi Pilati; Mario Gruppo Journal: J Clin Med Date: 2022-02-03 Impact factor: 4.241